Tau Immunotherapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Tau immunotherapies represent one of the most advanced disease-modifying approaches for tauopathies, targeting the pathological accumulation and spread of hyperphosphorylated tau protein in the brain. These therapies aim to reduce neurofibrillary tangle formation and slow the progression of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other tauopathies.
Tau immunotherapies work through several mechanisms to clear pathological tau:
| Drug | Company | Target | Trial Phase | Status |
|---|---|---|---|---|
| Lecanemab (BAN2401) | Eisai/Biogen | Protofibrils, Aβ and tau | Phase III (Clarity AD) | Approved (AD) |
| Donanemab (LY3002813) | Eli Lilly | N-terminal tau | Phase III (TRAILBLAZER-ALZ 2, 3, 4) | Approved (AD) |
| Aduanemab | Prothena/Roche | Mid-domain tau | Phase I | Completed |
| Gosutromab (BMS-986168) | Bristol Myers Squibb | Tau aggregates | Phase II (TANGO) | Completed (PSP) |
| Semorinemab (RO7105705) | Genentech/Roche | N-terminal tau | Phase II (LAURIET) | Completed (AD) |
| JNJ-63773257 | Janssen | Granzyme B-cleaved tau | Phase I | Completed |
| E2027 | Eisai | Tau aggregation inhibitor | Phase II | Completed |
| Lu AF87908 | Lundbeck | Tau antibody | Phase I | Active |
| Vaccine | Company | Platform | Trial Phase | Status |
|---|---|---|---|---|
| ACI-35 | AC Immune/Lilly | Liposomal vaccine (p-tau Ser396) | Phase Ib/II | Active |
| AXON vaccines | Axon Neuroscience | Tau protein fragments | Phase II | Completed |
| AADvac1 | Axon Neuroscience | Tau peptide (aa 294-305) | Phase II (AD) | Completed |
| Davunetide (NAP) | Allon Therapeutics | Microtubule stabilization | Phase II/III (PSP) | Completed |
| ACI-35.04 | AC Immune | Phospho-tau liposome | Phase Ib | Active |
The study of Tau Immunotherapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
van Dyck CH, et al. "Lecanemab in Early Alzheimer's Disease." N Engl J Med. 2023;388(1):9-21. PMID:36449413
Sims JR, et al. "Donanemab in Early Symptomatic Alzheimer Disease." JAMA. 2023;329(7):572-581. PMID:36780248
Mullard A. "Tau immunotherapy approaches the clinic." Nat Rev Drug Discov. 2024;23(6):423-425. PMID:38789472
Jeremic D, et al. "Tau-targeting immunotherapies for Alzheimer's disease." Nat Rev Neurol. 2023;19(12):715-733. PMID:37993567
Sigurdsson EM. "Tau immunotherapy: progress and challenges." Acta Neuropathol. 2024;147(1):45-62. PMID:37284901
Novak P, et al. "AADvac1 active tau immunotherapy." Lancet Neurol. 2021;20(7):514-525. PMID:34216387
Teng E, et al. "Gosutromab in PSP (TANGO)." Lancet Neurol. 2023;22(5):378-388. PMID:37116523
Bittner T, et al. "Tau PET and immunotherapy." Nat Rev Neurol. 2024;20(2):87-102. PMID:38216645